The present invention relates to an edible composition having a lipid continuous phase and self-assembled structures, the composition comprising oil, phospholipids, caffeine and water. Further aspects of the invention are the use of a composition to provide controlled release of caffeine, a composition for use in the treatment or prevention of drowsiness, the non-therapeutic use of a composition to increase mental alertness, and an edible capsule.

A processes for increasing the stability of a composition containing polyunsaturated an omega-6 fatty acid against oxidation proceeds by (i) providing a starting composition containing at least one polyunsaturated omega-6 fatty acid component; (ii) providing a lysine composition; (iii) admixing an aqueous, an aqueous-alcoholic or an alcoholic solution of starting composition and lysine composition, and subjecting a resulting admixture to spray drying conditions subsequently, thus forming a solid product composition containing at least one salt of a cation derived from lysine with an anion derived from the polyunsaturated omega-6 fatty acid; the product composition exhibiting a solvent content SC selected from the following; SC<5 wt %, SC<3 wt %, SC<1 wt %, or <0.5 wt %.

The present invention provides a novel peptide that has an amino acid sequence represented by SEQ ID NO: 18, and binds to an active protease but does not bind to a pro-protease.

Provided herein are methods for treating a sleep disorder, e.g., insomnia, in a subject, comprising administering to the subject an effective amount of a compound having the formula

##STR00001##

or a pharmaceutically acceptable salt thereof.

Provided herein are methods for treating a sleep disorder, e.g., insomnia, in a subject, comprising administering to the subject an effective amount of a compound having the formula

##STR00001##

or a pharmaceutically acceptable salt thereof.

The invention relates to heterocyclic angiotensin II type 2 (AT.sub.2) receptor antagonists of formula (I), and pharmaceutically acceptable salts thereof, ((I) in which all of the variables are as defined in the specification, pharmaceutical compositions thereof,combinations thereof, and their use as medic-aments, particularly for the treatment of neuropathic or inflammatory pain.

##STR00001##

The invention relates to 3α-ethynyl, 3β-hydroxy, 5α-pregnan-20-oxime or a pharmaceutically acceptable salt thereof, which compounds and/or salts are useful as modulators of the mammal brain excitability via the gamma-5 aminobutyric acid receptor-chloride ionophore (GABA.sub.A-R) complex and in the treatment of disorders such as hepatic encephalopathy, Down's syndrome and Alzheimer's disease.

The invention relates to compounds of formula (I) and salts thereof:

##STR00001##

wherein ring A and R.sup.1-R.sup.2 have any of the values defined in the specification. The compounds and salts are useful for treating DLK mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as methods of using said compounds, salts, or compositions as DLK inhibitors and for treating neurodegeneration diseases and disorders.

Provided are a novel agent or composition and others.

The agent or composition comprises caryophyllene and is used for at least one selected from the following (purposes) (1) to (3) : (1) promoting relaxation, prolonging a resting-state time, and/or prolonging a motionless time, (2) promoting sleep, and (3) preventing blood pressure elevation.

The present invention also relates to a method for inhaling β-caryophyllene simultaneously with smoking a tobacco product, characterized in that the tobacco product contains a β-caryophyllene-containing seamless capsule in a tobacco filter, wherein the seamless capsule contains an essential oil containing β-caryophyllene as an active ingredient. The applicants found that pulmonary inhalation of β-caryophyllene by the above method allows β-caryophyllene to be efficiently distributed throughout the body, leading to achievements of relaxing and sleep-inducing effects, etc.

The present invention relates to a medicament for treating various nervous system diseases or psychiatric diseases, comprising a compound of formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient, wherein R.sup.1 is hydrogen, etc., R.sup.2 is halogen, etc., R.sup.3, R.sup.4, R.sup.5, and R.sup.6 are hydrogen, etc.

##STR00001##